Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19201115 | 0.80 | KDR (0.44) | KDM4EALDH1A1CLK4HPGDHTT | |
| SCHEMBL7577615 | 0.76 | KDM4E (0.36) | KDM4EALDH1A1CLK4HPGDHTT | |
| SCHEMBL13990623 | 0.69 | NPC1 (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2PIM1 | |
| SCHEMBL4794157 | 0.68 | KDM4E (0.61) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL11776811 | 0.68 | TLR8 (0.51) | KDM4EALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL8992934 | 0.67 | GPR119 (0.47) | ALDH1A1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL10436137 | 0.64 | NTRK1 (0.33) | KDM4EHTTSMN1; SMN2PIM1NPC1 | |
| SCHEMBL1333523 | 0.64 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL30786518 | 0.64 | PDE10A (0.34) | AKT1 | |
| SCHEMBL8765848 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020036-A1 | TREATMENT OF EPILEPTIC CONDITIONS WITH GABAA RECEPTOR MODULATORS | NEUROCYCLE THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020036-A1 | TREATMENT OF EPILEPTIC CONDITIONS WITH GABAA RECEPTOR MODULATORS | GABRB2, GABRB1, GABBR1 | KDM4E 3783/4885ALDH1A1 1052/4885CLK4 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.